PRE-CONFERENCE WORKSHOP DAY

*times shown in EST

Workshop A

9:30am – 12:00pm

Discussing Treg Cell-based Therapy Challenges & Exploring How to Improve the Manufacturing Process

 

The development of Treg cell-based immunotherapies requires the effective ex vivo expansion to achieve the required numbers of clinical competent Treg cells. The standard procedure involves the isolation of suppressor T cells in a closed system of cell processing to enrich CD25+ T cells. Once isolated, most protocols use anti-CD3/ anti-CD28 beads and IL-2 in combination with Rapamycin to induce expansion of Tregs and prevent the outgrowth of CD25+ effector T cells. The last step is the collection of the expanded Treg cells free of the stimulating beads for infusion. We will discuss the challenges of each step and will address potential approaches to improve the manufacturing process.

Attend this workshop to:

  • Learn from our extensive clinical experience in transplantation
  • Discuss the challenges of the manufacturing process: purification, expansion, timelines, dosage and functional standards of Treg cells
  • Discover potential novel approaches to improve current standards
Workshop Leaders:
Francesc Marti

Francesc Marti
Associate Professor
University of Kentucky

Roberto Gedaly

Roberto Gedaly
Professor
University of Kentucky

Workshop B

9:30am – 12:00pm

Practical Approaches to Decreasing Treg Numbers & Function & Promote Anti-Tumor Immunity

 

The immunotherapy of cancer is basically stuck, doing more of the same (anti-PD-1, anti-PD-L1, anti-CTLA4) and getting the same limited results. Foxp3+ Treg cells curtail host responses to tumors and there is a major unmet need to find ways to diminish their actions. This presentation will discuss options for this using small molecules and anti-sense oligonucleotides based on data using syngeneic murine tumor studies and Tregs isolated from human lung cancers.

This workshop will cover:

  • Small molecules are available that decrease Treg numbers and/ or function but preserve T-effector responses
  • Antisense oligonucleotides can selectively impair Treg function
  • These agents can be used alone or in conjunction with checkpoint inhibitor therapies
Workshop Leader:
Wayne

Wayne Hancock
Professor
University of Pennsylvania

Workshop C

1:00pm – 3:30pm

Purification & Expansion of Regulatory T Cells

 

Clinical application of Tregs has historically been hampered by their unfavorable ex vivo expansion properties. This workshop will discuss and introduce techniques for purification and expansion of regulatory T cells.

 

This workshop will cover:

1. Introduction
2. Purification of Tregs Using Clini-MACS
3. Alternative Purification Methods – Flow Sorting
4. Quality Control of the Purified Treg Product
5. Polyclonal Expansion Protocol Used at
Northwestern
6. Polyclonal Expansion Protocols Used Elsewhere
7. Antigen Specific Treg Expansion Protocols
8. Bead Removal from Expanded Treg Products
9. Sterility Testing of Expanded Tregs
10. Functional Testing of Expanded Tregs
11. Clinical Experiences with the Expanded Treg Products
12. Post-infusion Immune Monitoring of
Patients
13. Concluding Remarks
Workshop Leaders:
James Mathew

James Mathew
Professor
Northwestern University

joseph

Joseph Leventhal
Professor
Northwestern University

Workshop D

1:00pm – 3:30pm

Characterization of Tumor Infiltration Tregs by scRNAseq

Despite the recent successes of checkpoint inhibitors in the treatment of various cancer types, majority of patients are still not
benefited from these treatments. Patients with the immune cold tumor types in general response poorly to checkpoint inhibitors, while many patients with hot cancers also cannot fully control cancer progress with anti-PD1 treatment alone.

This workshop will cover:

  • Discuss how we performed comprehensive single cell RNAseq analyses of tumor infiltrating T cells and other cell types from various cancer types in patients and in animal models to better understand the T cell dynamics and identify novel therapeutic strategies.
  • Explain how these analyses revealed novel properties of tumor infiltrating Tregs, especially their distribution dynamics and developmental trajectories.
  • Identification of new therapeutic targets for modulating Treg functions in tumor
Workshop Leader:
Wenjun Ouyang

Wenjun Ouyang
Executive Director
Amgen Inc